HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to conduct a Phase I - II clinical trial to extend preclinical
studies involving in situ HSV-tk + Valacyclovir gene therapy in combination with
brachytherapy for recurrent prostate cancer. This will provide a novel therapeutic approach
to prostate cancer and hopefully impact on the development of metastatic disease and the
control of preexisting metastasis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System